Adicet Bio Inc ASCO Update Call Transcript
Good afternoon, thank you for joining us. On the call today from Adicet are Chen Schor, President and CEO, Dr. Francesco Galimi, Chief Medical Officer; Nick Harvey, Chief Financial Officer; and Dr. Blake Aftab, Chief Scientific Officer.
In addition, we're very pleased to have Dr. Sattva Neelapu professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center joining us today.
Before we begin, I'd like to remind you that various remarks that we make on this call contain forward-looking statements that are made under the safe harbor provisions of the securities laws, including, but not limited to, expressed or implied statements regarding the potential safety durability, tolerability and therapeutic effects of ADI-001, including the expected design, implementation, timing and success of ADI-001, plans and timing for the release of additional clinical data from Adicet's Phase I trial of ADI-001, in relapsed, refractory NHL patients, future progress of the GLEAN study, including ongoing patient enrollment expectations
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
